Economics and the new generation of targeted therapies for non-small cell lung cancer.
Ramsey
Scott D
SD
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D002170:Canada; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000191:economics; D003362:Cost-Benefit Analysis; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000191:economics; D047428:Protein Kinase Inhibitors / Q000191:economics / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011799:Quinazolines / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014481:United States
D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D011505:Protein-Tyrosine Kinases